I-Mab (IMAB) Competitors $2.12 +0.01 (+0.47%) Closing price 04:00 PM EasternExtended Trading$2.10 -0.02 (-0.71%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMAB vs. MAZE, MRVI, IOVA, URGN, TLRY, TNGX, STOK, PRME, DNTH, and PHATShould you be buying I-Mab stock or one of its competitors? The main competitors of I-Mab include Maze Therapeutics (MAZE), Maravai LifeSciences (MRVI), Iovance Biotherapeutics (IOVA), Urogen Pharma (URGN), Tilray Brands (TLRY), Tango Therapeutics (TNGX), Stoke Therapeutics (STOK), Prime Medicine (PRME), Dianthus Therapeutics (DNTH), and Phathom Pharmaceuticals (PHAT). These companies are all part of the "pharmaceutical products" industry. I-Mab vs. Its Competitors Maze Therapeutics Maravai LifeSciences Iovance Biotherapeutics Urogen Pharma Tilray Brands Tango Therapeutics Stoke Therapeutics Prime Medicine Dianthus Therapeutics Phathom Pharmaceuticals Maze Therapeutics (NASDAQ:MAZE) and I-Mab (NASDAQ:IMAB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment and dividends. Is MAZE or IMAB more profitable? Maze Therapeutics' return on equity of 0.00% beat I-Mab's return on equity.Company Net Margins Return on Equity Return on Assets Maze TherapeuticsN/A N/A N/A I-Mab N/A -19.81%-18.63% Does the media refer more to MAZE or IMAB? In the previous week, Maze Therapeutics had 6 more articles in the media than I-Mab. MarketBeat recorded 8 mentions for Maze Therapeutics and 2 mentions for I-Mab. Maze Therapeutics' average media sentiment score of 0.38 beat I-Mab's score of 0.15 indicating that Maze Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maze Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral I-Mab 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher earnings & valuation, MAZE or IMAB? Maze Therapeutics has higher revenue and earnings than I-Mab. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMaze Therapeutics$167.50M4.30$52.23MN/AN/AI-Mab$3.89M44.50-$22.23MN/AN/A Do institutionals and insiders hold more shares of MAZE or IMAB? 38.4% of I-Mab shares are held by institutional investors. 22.1% of I-Mab shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts recommend MAZE or IMAB? Maze Therapeutics presently has a consensus target price of $25.60, suggesting a potential upside of 55.62%. I-Mab has a consensus target price of $6.00, suggesting a potential upside of 183.02%. Given I-Mab's stronger consensus rating and higher possible upside, analysts clearly believe I-Mab is more favorable than Maze Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maze Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29I-Mab 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 SummaryMaze Therapeutics beats I-Mab on 8 of the 13 factors compared between the two stocks. Get I-Mab News Delivered to You Automatically Sign up to receive the latest news and ratings for IMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMAB vs. The Competition Export to ExcelMetricI-MabMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$173.12M$3.05B$5.67B$9.49BDividend YieldN/A2.44%4.05%4.00%P/E RatioN/A20.8627.9419.96Price / Sales44.50246.07396.5882.69Price / CashN/A41.9636.1958.45Price / Book0.868.308.635.82Net Income-$22.23M-$55.19M$3.24B$258.42M7 Day Performance-1.85%5.06%3.22%1.94%1 Month Performance-10.55%17.59%10.71%12.02%1 Year Performance50.35%7.02%34.94%20.81% I-Mab Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMABI-Mab2.7376 of 5 stars$2.12+0.5%$6.00+183.0%+47.6%$173.12M$3.89M0.00380Gap DownMAZEMaze TherapeuticsN/A$15.74+4.6%$23.50+49.3%N/A$689.41M$167.50M0.00121News CoverageAnalyst ForecastMRVIMaravai LifeSciences3.6352 of 5 stars$2.67-2.2%$6.64+148.6%-68.6%$679.94M$259.18M-2.34610Options VolumeIOVAIovance Biotherapeutics4.6082 of 5 stars$2.01+7.5%$12.22+508.1%-54.3%$671.20M$164.07M-1.62500Analyst ForecastOptions VolumeGap DownHigh Trading VolumeURGNUrogen Pharma4.4833 of 5 stars$14.49+1.8%$32.86+126.8%+10.2%$668.13M$90.40M-4.56200TLRYTilray Brands1.8877 of 5 stars$0.66+13.1%$1.92+191.8%-61.1%$661.07M$788.94M-0.632,650Upcoming EarningsOptions VolumeTNGXTango Therapeutics1.3436 of 5 stars$6.09+2.7%$12.20+100.3%-29.4%$660.12M$40.99M-4.9990STOKStoke Therapeutics4.2499 of 5 stars$12.06+1.7%$24.75+105.2%-2.1%$658.48M$36.56M15.27100PRMEPrime Medicine3.9766 of 5 stars$4.80+10.3%$10.08+110.1%-19.9%$645.57M$3.85M-2.34234High Trading VolumeDNTHDianthus Therapeutics0.9186 of 5 stars$20.03-0.1%$53.00+164.6%-21.0%$644.17M$6.24M-6.9580PHATPhathom Pharmaceuticals4.3723 of 5 stars$9.06-1.3%$17.50+93.2%-29.3%$632.48M$55.25M-1.73110 Related Companies and Tools Related Companies Maze Therapeutics Alternatives Maravai LifeSciences Alternatives Iovance Biotherapeutics Alternatives Urogen Pharma Alternatives Tilray Brands Alternatives Tango Therapeutics Alternatives Stoke Therapeutics Alternatives Prime Medicine Alternatives Dianthus Therapeutics Alternatives Phathom Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMAB) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon Just Fired the IRS Agents Targeting Your SavingsElon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regai...Priority Gold | SponsoredTrump’s $100 Trillion Land Rush Is OnWhat Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trill...Stansberry Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredFREE GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding I-Mab Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share I-Mab With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
